Adenosine as a neuromodulator in neurological diseases

被引:181
作者
Boison, Detlev [1 ]
机构
[1] RS Dow Neurobiol Labs, Portland, OR 97232 USA
关键词
D O I
10.1016/j.coph.2007.09.002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adenosine is a modulator of brain function uniquely positioned to integrate excitatory and inhibitory neurotransmission. The past few years brought a wealth of new data fostering our understanding of how the adenosine system is involved in the pathogenesis of neurological diseases. Thus, dysregulation of the adenosine system is implicated in epileptogenesis and cell therapies have been developed to locally augment adenosine in an approach to prevent seizures. While activation of inhibitory adenosine A, receptors is beneficial in epilepsy, chronic pain and cerebral ischemia, inhibition of facilitatory A(2A) receptors has profound neuroprotective effects, which are currently exploited in clinical trials in Parkinson's disease. A new era of adenosine-based therapies has begun, with the prospect to cover a wide range of neurological diseases.
引用
收藏
页码:2 / 7
页数:6
相关论文
共 50 条
  • [1] Hypoglycemic seizures during transient hypoglycemia exacerbate hippocampal dysfunction
    Abdelmalik, Peter A.
    Shannon, Patrick
    Yiu, Adelaide
    Liang, Philip
    Adamchik, Yana
    Weisspapir, Michael
    Samoilova, Marina
    Burnham, W. McIntyre
    Carlen, Peter L.
    [J]. NEUROBIOLOGY OF DISEASE, 2007, 26 (03) : 646 - 660
  • [2] Caffeine protects Alzheimer's mice against cognitive impairment and reduces brain β-amyloid production
    Arendash, G. W.
    Schleif, W.
    Rezai-Zadeh, K.
    Jackson, E. K.
    Zacharia, L. C.
    Cracchiolo, J. R.
    Shippy, D.
    Tan, J.
    [J]. NEUROSCIENCE, 2006, 142 (04) : 941 - 952
  • [3] Adenosine and epilepsy: From therapeutic rationale to new therapeutic strategies
    Boison, D
    [J]. NEUROSCIENTIST, 2005, 11 (01) : 25 - 36
  • [4] Adenosine-based cell therapy approaches for pharmacoresistant epilepsies
    Boison, Detlev
    [J]. NEURODEGENERATIVE DISEASES, 2007, 4 (01) : 28 - 33
  • [5] Cell and gene therapies for refractory epilepsy
    Boison, Detlev
    [J]. CURRENT NEUROPHARMACOLOGY, 2007, 5 (02) : 115 - 125
  • [6] Adenosine kinase, epilepsy and stroke: mechanisms and therapies
    Boison, Detlev
    [J]. TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (12) : 652 - 658
  • [7] Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers
    Ciruela, F
    Casadó, V
    Rodrigues, RJ
    Luján, R
    Burgueño, J
    Canals, M
    Borycz, J
    Rebola, N
    Goldberg, SR
    Mallol, J
    Cortés, A
    Canela, EI
    López-Giménez, JF
    Milligan, G
    Lluis, C
    Cunha, RA
    Ferré, S
    Franco, R
    [J]. JOURNAL OF NEUROSCIENCE, 2006, 26 (07) : 2080 - 2087
  • [8] Neuroprotection by adenosine in the brain: From A1 receptor activation to A2A receptor blockade
    Cunha R.A.
    [J]. Purinergic Signalling, 2005, 1 (2) : 111 - 134
  • [9] Tonic adenosine A1 and A2A receptor activation is required for the excitatory action of VIP on synaptic transmission in the CA1 area of the hippocampus
    Cunha-Reis, D.
    Fontinha, B. M.
    Ribeiro, J. A.
    Sebastiao, A. M.
    [J]. NEUROPHARMACOLOGY, 2007, 52 (02) : 313 - 320
  • [10] Caffeine and adenosine A2a receptor antagonists prevent β-amyloid (25-35)-induced cognitive deficits in mice
    Dall'Igna, Oscar P.
    Fett, Paulo
    Gomes, Marcio W.
    Souza, Diogo O.
    Cunha, Rodrigo A.
    Lara, Diogo R.
    [J]. EXPERIMENTAL NEUROLOGY, 2007, 203 (01) : 241 - 245